These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 1666497)

  • 21. Pharmacokinetics and biliary elimination of temafloxacin in pigs.
    Jehl F; Bresler L; Koechlin C; Merle-Melet M; Didelot JP; Hazebroucq J
    J Antimicrob Chemother; 1992 Aug; 30(2):189-96. PubMed ID: 1328135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinafloxacin pharmacokinetics in subjects with various degrees of renal function.
    Randinitis EJ; Koup JR; Rausch G; Abel R; Bron NJ; Hounslow NJ; Vassos AB; Sedman AJ
    Antimicrob Agents Chemother; 2001 Sep; 45(9):2536-42. PubMed ID: 11502526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of carumonam (AMA-1080) in patients with impaired renal function and in those undergoing hemodialysis.
    Konishi K; Suzuki H; Saruta T; Deguchi N; Fugono T
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1048-52. PubMed ID: 1929242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of butorphanol nasal spray in patients with renal impairment.
    Shyu WC; Morgenthien EA; Barbhaiya RH
    Br J Clin Pharmacol; 1996 May; 41(5):397-402. PubMed ID: 8735680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Penetration of temafloxacin into body tissues and fluids.
    Sörgel F
    Clin Pharmacokinet; 1992; 22 Suppl 1():57-63. PubMed ID: 1319872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disposition of minoxidil in patients with various degrees of renal function.
    Halstenson CE; Opsahl JA; Wright CE; Fleishaker JC; Andreadis NA; Sobieraj J; Matzke GR
    J Clin Pharmacol; 1989 Sep; 29(9):798-802. PubMed ID: 2808745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatobiliary elimination of temafloxacin.
    Sörgel F; Granneman GR; Mahr G; Kujath P; Fabian W; Nickel P
    Clin Pharmacokinet; 1992; 22 Suppl 1():33-42. PubMed ID: 1319869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of pregabalin in subjects with various degrees of renal function.
    Randinitis EJ; Posvar EL; Alvey CW; Sedman AJ; Cook JA; Bockbrader HN
    J Clin Pharmacol; 2003 Mar; 43(3):277-83. PubMed ID: 12638396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isepamicin disposition in subjects with various degrees of renal function.
    Halstenson CE; Kelloway JS; Affrime MB; Lin CC; Teal MA; Shapiro BE; Awni WM
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2382-7. PubMed ID: 1804011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of sparfloxacin in patients with renal impairment.
    Fillastre JP; Montay G; Bruno R; Etienne I; Dhib M; Vivier N; Le Roux Y; Guimart C; Gay G; Schott D
    Antimicrob Agents Chemother; 1994 Apr; 38(4):733-7. PubMed ID: 8031038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine.
    Mahr G; Sörgel F; Granneman GR; Kinzig M; Muth P; Patterson K; Fuhr U; Nickel P; Stephan U
    Clin Pharmacokinet; 1992; 22 Suppl 1():90-7. PubMed ID: 1319876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency.
    Kneer J; Tam YK; Blouin RA; Frey FJ; Keller E; Stathakis C; Luginbuehl B; Stoeckel K
    Antimicrob Agents Chemother; 1989 Nov; 33(11):1952-7. PubMed ID: 2610506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment.
    Boike SC; Pue MA; Freed MI; Audet PR; Fairless A; Ilson BE; Zariffa N; Jorkasky DK
    Clin Pharmacol Ther; 1994 Apr; 55(4):418-26. PubMed ID: 8162668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cefsulodin kinetics in renal impairment.
    Gibson TP; Granneman GR; Kallal JE; Sennello LT
    Clin Pharmacol Ther; 1982 May; 31(5):602-8. PubMed ID: 7075110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of sparfloxacin in patients with renal impairment.
    Dorr MB; Johnson RD; Jensen B; Magner D; Marbury T; Talbot GH
    Clin Ther; 1999 Jul; 21(7):1202-15. PubMed ID: 10463518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cefonicid kinetics in subjects with normal and impaired renal function.
    Blair AD; Maxwell BM; Forland SC; Jacob L; Cutler RE
    Clin Pharmacol Ther; 1984 Jun; 35(6):798-803. PubMed ID: 6734031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disposition of cefmetazole in healthy volunteers and patients with impaired renal function.
    Halstenson CE; Guay DR; Opsahl JA; Hirata CA; Olanoff LS; Novak E; Ko H; Cathcart KS; Matzke GR
    Antimicrob Agents Chemother; 1990 Apr; 34(4):519-23. PubMed ID: 2344159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects.
    Bron NJ; Dorr MB; Mant TG; Webb CL; Vassos AB
    J Antimicrob Chemother; 1996 Dec; 38(6):1023-9. PubMed ID: 9023649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Steady-state intravenous pharmacokinetics of pirenzepine in patients with differing degrees of renal dysfunction.
    Krakamp B; Tanswell P; Vogel H; Bozler G
    Eur J Clin Pharmacol; 1989; 36(1):75-8. PubMed ID: 2917593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of food on the bioavailability of temafloxacin. A review of 3 studies.
    Granneman GR; Mukherjee D
    Clin Pharmacokinet; 1992; 22 Suppl 1():48-56. PubMed ID: 1319871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.